Revenue segments as reported by the company.

Proprietary Products

Contract - Manufactured Products

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Other (income) expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

West Pharmaceutical Services reports solid growth and strategic investments

West Pharmaceutical Services showed resilience with 8% organic sales growth in 2022 despite challenges.
2023 guidance includes growth projections, margin expansion, and a share repurchase program.
The company's pricing strategy and investments in high-value products position it for future success.
Despite COVID impacts, West remains focused on growth opportunities and sustainability efforts.

West Pharmaceutical Services reports solid Q1 performance and growth outlook

West Pharmaceutical Services (WST) showcased strong Q1 performance with growth in key market units and ongoing investments in capacity expansion.
Despite challenges such as declining profitability metrics and inflationary pressures, the company remains optimistic about its full-year outlook and growth prospects.
Opportunities lie in sustained growth in Contract Manufacturing, revenue diversification, and a focus on margin expansion to drive future financial success.
Analysts' inquiries highlighted areas for improvement, signaling a proactive approach to addressing challenges and capitalizing on growth opportunities.

West Pharmaceutical Services excels in Q2, eyes growth opportunities

West Pharmaceutical Services reported strong Q2 performance driven by key business units and growth drivers, with a focus on sustainability and capacity investments. Despite challenges like margin expectations and external events, the company remains well-positioned for growth. Opportunities lie in revenue pickup in Q4, strategic partnerships, and global market expansion.

West Pharmaceutical Services reports solid Q3 performance and eyes growth through automation and strategic investments

West Pharmaceutical Services delivered solid Q3 performance with growth in net sales and adjusted EPS, despite challenges in inventory management and capacity constraints.
The company's strategic investments in automation and capacity expansions position it well for future growth opportunities in HVP and biologics.
While facing industry challenges and uncertainties, West remains confident in meeting or exceeding its growth targets for 2024 through continuous monitoring and adjustment.
Maintaining a strong focus on customer commitments and market differentiation, West Pharmaceutical Services aims to drive growth through innovation and operational efficiency.

West Pharmaceutical Services reports solid Q4 results amidst 2024 challenges

West Pharmaceutical Services navigated challenges in Q4 2023 with solid performance and a focus on growth drivers for 2025, despite anticipated hurdles in 2024.
The company's strategic approach to capital allocation, market share strength, and product focus position it well for future growth and resilience.
Balancing challenges with opportunities, West Pharmaceutical Services aims to sustain growth momentum, overcome obstacles, and drive efficiency and innovation.
With a strong order book outlook, normalized margin rates, and a focus on market trends, West Pharmaceutical Services is poised for continued success and market leadership.

West Pharmaceutical Services navigates mixed Q1 performance with strategic resilience

West Pharmaceutical Services faced challenges in Q1 2024 but demonstrated strengths in strategic planning and resilience.
The company's focus on capacity expansions and maintaining guidance reflects a commitment to long-term growth.
Addressing challenges related to customer destocking and financial performance will be crucial for seizing opportunities and enhancing competitiveness.

West Pharmaceutical Services faces Q2 challenges but eyes future growth

West Pharmaceutical Services navigated challenges in Q2 2024 due to customer destocking, impacting organic sales and gross profit margin. Despite this, management remains optimistic about future growth prospects, aiming to return to a 7% to 9% growth construct. Adjusted full-year guidance reflects a more gradual recovery, with a focus on strategic investments for future growth.

West Pharmaceutical Services reports solid Q3 results amid margin challenges

West Pharmaceutical Services reported solid Q3 performance but faced declines in key financial metrics compared to the previous year. The company is focusing on leveraging its strengths in biologics and expertise to drive future growth, while addressing challenges in margins and organic sales. Opportunities lie in improving performance in Q4 and capitalizing on increased guidance for net sales and adjusted EPS.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Joint

Patterson Companies

ResMed

Here are some MedTech stocks which might be solid investment options for profit-maximization amid the coronavirus-led market mayhem.

4 Best MedTech Stocks to Combat Coronavirus Crisis on Strong ROE

DaVita

Once the pandemic-led crisis is over, these MedTech growth-focused stocks will flourish on a number of positive developments.

3 Growth-Focused MedTech Stocks to Buy Amid Coronavirus Crisis

EXTON, Pa., July 9, 2020 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release second-quarter 2020 financial results before the market opens on Thursday, July 23,...

West to Host Second-Quarter 2020 Conference Call

The stock price of West Pharmaceutical Services, best known for injectable pharmaceutical packaging and delivery systems, has rallied around 78% over recent weeks (vs. about a 40% gain in the S&P 500) to its current level of $230, after falling to a low of $129 in late March as a rapid increase.

What’s Next For West Pharmaceutical Services After An 80% Rally?

DexCom

Seagen

Teladoc

Vertex Pharmaceuticals

Teladoc Health, Dexcom, Vertex Pharmaceuticals, Seattle Genetics and West Pharmaceutical Services are medical stocks in or near buy zones.
The post Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones appeared first on Investor's Business Daily.

Teladoc, Dexcom, Vertex, Seattle Genetics, West Pharmaceutical: Five Medical Stocks In Or Near Buy Zones

Applied Industrial Technologies

Buckle

Cracker Barrel Old Country Store

Invesco Dynamic Leisure and Entertainment ETF

Industrial Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

SPDR S&P Retail ETF

The U.S. economy unexpectedly added 4.8 million jobs in June, breezing past economists??? expectations of job gains of 2.9 million.

Jobs Market Strengthening Fast: 4 Sector ETFs & Stocks to Buy

NextEra Energy

NICE Ltd

Teekay Tankers

Tesla

Investors should know how much debt a company owns, because the higher the degree of financial leverage, higher is the interest payment for the capital borrowed.

5 Low Leverage Stocks to Buy Amid Coronavirus-Led Debacle

McCormick

Procter & Gamble

ESG policies and practices yielded positive outcomes during the coronavirus slump. Also, millennials-driven sustainable investing trend will continue post-pandemic.

Sustainable Investment Forms Part of the New Normal: 5 Picks

Amgen

Anthem

Bristol-Myers

Guardant Health Inc

Iovance Biotherapeutics

IQVIA Hlds

Medtronic

Veeva Systems

Acceleron Pharma

The pandemic has put the health care industry under a global spotlight.

10 Stocks to Invest in the Health Care Revolution

AbbVie

W.W. Grainger

Kroger

Taiwan Semiconductor Manufacturing

The second wave of coronavirus infections has flared up volatility and made investors scurry for safety and regular income. This has resulted in higher appeal for dividend investing.

5 Great Dividend Growth Stocks Amid Market Volatility

Dolby Laboratories

MKS Instruments

Benjamin Graham, the father of value investing, recommended screening for stocks that have a current ratio of more than 2 and more working capital than long-term debt, as these measures indicate solid balance sheets.

3 High Quality Stocks for the Value Investor

Fortinet

MarketAxess Holdings

NVIDIA

Tractor Supply

Today marks 100 days since the World Health Organization declared COVID-19 a pandemic on Mar 11. We have highlighted some stocks from the S&P 500 index that soared more than 40% during this period.

5 S&P 500 Winners of 100 Days of Coronavirus Pandemic

Here're five big stock winners from the first 100 days of the coronavirus pandemic that ravaged the global economy and shook the stock market.

5 Best Stocks From 100 Days of Coronavirus

AngioDynamics

Channeladvisor

Lakeland Industries

Exorbitant debt financing might even cause a corporation's bankruptcy in the worst-case scenario.

Buy These 5 Low Leverage Stocks to Avoid Debt-Related Risk

Masimo

Finding Health Care Companies We Believe Can Thrive In A Post-COVID-19 Environment

Clorox

Everbridge

These frontrunners are currently witnessing a short-term pullback in price. So make sure you're taking full advantage of it.

Top 3 Momentum Anomaly Stocks to Consider on Investor Optimism

iShares U.S. Home Construction ETF

KB Home

VanEck Vectors Retail ETF

Sportsman's Warehouse Hlds

The U.S. jobs report for the month of May reflected the largest one-month job gains.

4 Sector ETFs & Stocks to Buy on Record Jobs Gain in May

Carrier Global

Newmont Mining

NortonLifeLock

ServiceNow

PayPal

Regeneron Pharmaceuticals

In a year dominated by COVID-19 news, many of the top-performing companies were boosted by the pandemic, but the top performer benefited from longer-term trends.

Top Performers in the S&P 500 This Year

Chemed

Synopsys

Debt financing is a feasible option as long as the companies succeed in generating a higher rate of return compared to the interest rate

Buy These 5 Low Leverage Stocks to Invest Safely

Applied Materials

Dollar General

Investors are once again in search for consistent and safe income in a near-zero interest environment, a series of drastic dividend cuts and rising U.S.-China tension.

Looking for Dividend Growth? Here Are 5 Solid Picks

News for West Pharmaceutical Services Stock (WST)